Authors

Latest:

Dr. Mato on the Potential Use of Noncovalent BTK Inhibitors in CLL

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center

Latest:

The Future of the Treatment Landscape in MZL and FL

Key opinion leaders in hematology-oncology consider the future treatment landscape for marginal zone and follicular lymphomas and reflect on the role of chemotherapy and targeted agents as induction or maintenance.

Anthony P. Conley, MD, The University of Texas MD Anderson Cancer CenterSyma Iqbal, MD, UCS Norris Comprehensive Cancer Center

Anthony P. Conley, MD, University of Texas MD Anderson Cancer Center

Anthony R. Mato, MD

Latest:

Noncovalent BTK Inhibitors in CLL

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Anthony R Mato, MD, Memorial Sloan Kettering Cancer Center

Anthony R. Mato, MD, MSCE

Latest:

Pirtobrutinib and Other Non-Covalent BTK Inhibitors in the Treatment of CLL

The assembled faculty comment on data on the role of non-covalent BTK inhibitors in the CLL treatment landscape, with emphasis on the phase 1/2 BRUIN trial of pirtobrutinib.

Anthony R. Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center

Anthony S. Stein, MD

Latest:

Dr. Stein on Blinatumomab for Relapsed/Refractory ALL

Anthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.

Anthony S. Stein, MD, Hematologic Malignancies

Anthony Shields, MD, PhD

Latest:

Dr. Shields on the Standard of Care in Newly Diagnosed mCRC

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Anthony Stein Gehr Family Center for Leukemia Research

Anthony W. Tolcher, MD

Latest:

Dr. Tolcher on Utomilumab Plus Pembrolizumab in Advanced Solid Tumors

Anthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics San Antonio, discusses a phase Ib study examining the combination of the 4-1BB agonist utomilumab (PF-05082566) and pembrolizumab (Keytruda) as a treatment for patients with advanced solid tumors.

Antoinette Wozniak, MD, FACP, FASCO

Latest:

Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

Antoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.

Antoni Ribas, MD

Latest:

Melanoma: Improving Clinical Outcomes Through Advances in Immunotherapeutics and Targeted Therapy

Metastatic melanoma has limited treatment options, but advances in the understanding of the oncogenic mutations that drive this cancer and how the immune system can be better modulated to fight melanoma provide a new generation of active approaches for patients.

Antoni Ribas, MD, PhD

Latest:

Dr. Ribas on Immune-Related Adverse Events in Melanoma

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.

Antoni Ribas, MD, PhD, University of California Los Angeles

Antonio C. Wolff, MD

Latest:

Dr. Wolff Discusses the Importance of HER2 Testing

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Antonio Gonzalez-Martin, MD

Latest:

Dr Gonzalez-Martin on the Efficacy of TUB-040 in Ovarian Cancer

Antonio Gonzalez-Martin, MD, discusses the key efficacy findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Antonio Iavarone, MD

Latest:

Dr. Iavarone on the Role of the ID2 Protein in Brain Cancer

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.